HR2976: Deferment for Active Cancer Treatment Act of 2017

Article

A no-brainer bill about student loans for young adult cancer patients that I spent a day advocating for. You can help - read to the end!

On June 21, 2017, I spent the day in surgery, getting my chemo port removed (in an elaborate imagining of it as a sequel to the Avengers).

This year, I spent the same day quite differently - I was advocating for HR2976 on Capitol Hill, as part of the first Young Adult Cancer Action Day (YACAD) organized by Critical Mass.

The bill, also known as the "Deferment for Active Cancer Treatment Act of 2017" is relatively simple. It asks that student loans payments and interest are deferred during active cancer treatment. While one can defer loans for a short time, it is subject to an arbitrary approval process by the lender and interest is still accrued, even while payments are not required.

No one expects to get cancer, especially not young adults. While there are 70,000 new young adult cancer diagnoses every year, this comes at the time in their life when they are supposed to be building a career, net worth and a new life. I was diagnosed with testicular cancer at 25 and I definitely know how it feels to have everything come to a grinding halt.

Many young adults already have student loans to repay. Having to pay these, on top of medical bills, can be downright impossible, especially on short-term disability income. Often, a patient has to make an incredibly hard choice: pay the medical bills and accumulate more debt on student loans or make payments on the loans and skimp on cancer care. No matter what, it can have long-lasting repercussions on credit and the future.

To be completely honest, I do not have student loans to contend with, thanks to a college fund my parents and grandparents set up for me when I was born. While it was not the most exciting thing to hear, "We put more money in your college fund for your birthday" while I was growing up, I definitely was appreciative of it once I graduated high school.

Due to this fact, I felt like I didn't really have a horse in the race. However, I thought back to how stressful it was trying to keep up with medical bills during chemotherapy. One smaller bill slipped through the cracks (largely due to chemo brain) and I ended up being sent to a collections agency. It was easy to get that straightened out, but I'm sure it's not that easy with student loan payments.

I learned of this firsthand from my fellow advocates as we met with various members of the US House of Representatives and their aides. One thyroid cancer survivor racked up $500 of interest during a deferment period, which was due upon resuming payments. Another bladder cancer patient, who is still in active treatment, is on short-term medical leave. He has a monthly income of about $700, and loan payments of roughly $500. This only leaves him a paltry sum of about $200 for living expenses and his medical bills.

The various people we met with were somewhat shocked that this wasn't already a law. Many of them said that it seemed like a "no brainer." It's not asking to forgive the loans; it's just "pressing pause." After the patient has completed active treatment, the bill gives a six-month grace period before the original terms of the original loan resumes. There's no downside to anyone in this situation, and many reps were happy to take a closer look and potentially become a co-sponsor.

As of this writing, there are 60 bipartisan co-sponsors of HR2976, which doesn't even include the new people we spoke to on YACAD.

This is where you can help. By visiting this link and entering your name, email address, and physical address, a letter will be generated to your US Representative. All you have to do is press "Send" and it does the rest for you. I just did it and it literally took longer to type this explanation than to actually do it.

There's no time like the present - go do it right now! The goal is to get this signed into law by the end of the year, since the bill's original sponsor is retiring, and the process will reset if it's not passed by then.

While you may not be a young adult cancer patient or have student loans, this is a commonsense measure that can help improve the lives of others.

Related Videos
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Related Content